“The Global Fund to Fight AIDS, Tuberculosis and Malaria said in a statement Thursday that its board had terminated the employment of Inspector General John Parsons ‘after a careful review of his performance, which was found to be unsatisfactory,'” the Associated Press reports (11/15). “The decision … , which was effective immediately, was based on a review by the board, an independent external peer review of the audit function, and a report by the group’s audit and ethics committee,” Reuters notes (Nebehay, 11/15). In a statement, the Global Fund said, “The Board confirms its full support for an independent and strong Office of the Inspector General.” The statement continues, “The Board said that it recognized the need to maintain continuity in the work of the audits and investigations currently underway, while the Global Fund conducts a search for a new Inspector General.” That process is expected to take about six months, and an interim Inspector General will be appointed soon, according to the statement (11/15).
The Global Fund to Fight AIDS, Tuberculosis and Malaria on Wednesday said an investigation by the group’s Inspector General into grants in Cambodia “uncovered credible and substantive evidence of serious financial wrongdoing, on procurement and other issues,” Agence France-Presse reports (11/15). In a statement, the organization said, “Immediate action has been taken to protect the health of people supported by Global Fund grants in Cambodia, by adopting safeguards in procurement, financing and management” and added it “is committed to maintaining its grants in Cambodia and to expanding safeguards to protect its investments.” The statement adds, “An investigation report by the Office of the Inspector General is being finalized, and is expected to be publicly released once it is completed in the coming weeks” (11/14). According to AFP, “The mismanaged money amounts to under $1 million and was allocated to Cambodian officials to spend on anti-malaria programs, said a source with knowledge of the investigation, speaking on condition of anonymity” (11/15).
Writing in Huffington Post’s “The Big Push” blog, Lucy Chesire, executive director and secretary to the board of the TB ACTION Group, notes “countries from north and south, U.N. organizations, private sector companies and [non-governmental organizations (NGOs)] are meeting in Geneva [this week] at the Board meeting of the Global Fund to Fight AIDS, Tuberculosis and Malaria to discuss how best to invest available resources against the three killer diseases.” She highlights “a new approach to fight AIDS, which basically could lead to the end of the global pandemic,” noting, “UNAIDS calls it ‘the people-centered investment approach.'” Chesire interviews Bernhard Schwartlander, director of evidence, innovation and policy at UNAIDS, about this new approach.
The Affordable Medicines Facility-malaria began as a pilot program in 2010 to “provide a ‘co-payment’ to the manufacturers of [artemisinin-based combination therapies (ACTs)], thereby allowing commercial wholesalers and private or government health services to purchase the drugs at a fraction of the already low negotiated price,” Kenneth Arrow, a Nobel laureate in economic sciences in 1972 and an emeritus professor of economics at Stanford University, writes in a New York Times opinion piece. The program subsidized ACTs — a newer, more effective malaria treatment — to “sell [them] as cheaply as [less-effective] chloroquine in Africa’s private pharmacies and shops, where half of all patients first seek treatment for malaria-like fevers,” he states. “Strikingly, it has worked,” Arrow writes, noting a recent independent review of the program published in the Lancet.
Recent successes in increasing the treatment and decreasing the incidence of HIV/AIDS, tuberculosis (TB), and malaria, along with other global health advances, “is thanks to the hard work and cooperation of people from many different walks of life: politicians of all stripes, business leaders, grassroots activists, clergy, health workers, government agencies and many more,” Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, writes in the Huffington Post “Impact” blog. She says the Global Fund to Fight AIDS, Tuberculosis and Malaria has been “[c]entral” to these developments, and the “U.S. government has been a crucial leader in supporting international health and the Global Fund.” She adds, “Sustained commitment will ensure more lifesaving success.” Derrick also recognizes the work of doctors and businesses.
The BMJ examines the history of fraud allegations against the Global Fund to Fight AIDS, Tuberculosis and Malaria and the organization’s ongoing reform efforts. “Most observers agree that after a honeymoon first decade, the Global Fund had grown so big, and the economic climate and attitudes to diseases such as AIDS have changed so dramatically, that more rigor and efficiency was needed, fraud or no fraud,” BMJ writes. The Fund is expected to appoint a new director “and a new funding model, to be announced on November 15, [which] are supposed to get things back on track” (Arie, 11/12).
“Look in the global strategies for HIV, [tuberculosis (TB)], malaria, maternal and child health, polio eradication, [neglected tropical diseases (NTDs)], and [non-communicable disease (NCDs)] — among many others — and you’ll see Nigeria at or near the top of the ‘Must Win’ countries,” Todd Summers, a senior adviser at the Center for Strategic & International Studies’ (CSIS) Global Health Policy Center, writes in the CSIS “Smart Global Health” blog. “Home to 170 million people, many of them desperately poor, Nigeria carries a huge and disproportionate share of burden for many of the world’s most deadly diseases,” he writes, noting the country, “one of the most important countries for all three diseases, is losing more in revenues than all of the Global Fund’s annual contributions combined.” He continues, “So, somehow, the Nigerian government needs to do a better job of capturing the revenues it’s due, and channeling a greater percentage of that revenue to the urgent health needs of its citizens, but that doesn’t seem to be happening.” However, Summers concludes “there’s some good news to report” on overall governance in the country, and he provides some examples (11/8).
The Global Fund to Fight AIDS, Tuberculosis and Malaria has published Issue 11 of its newsletter, the “Global Fund News Flash.” The issue focuses on program impact, reporting that “the Global Fund [last week] approved a country impact evaluation plan to support its strategy of investing for impact,” and noting “[a] management focus on impact helps programs prioritize activities, identify risks, and steer investments toward gaps in coverage.” The newsletter goes on to examine the Global Fund’s “efforts to build impact assessment into its business model,” as well as efforts to reach the health-related Millennium Development Goals in Ethiopia (11/7).
Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, on Monday published Issue 201 of its “Global Fund Observer.” Among other articles, the issue features an article on a recently released Aidspan paper examining how the Global Fund calculates lives saved; a commentary on how the Global Fund’s new funding model will affect its Latin America and the Caribbean portfolio; and an article examining five new reports from the Office of the Inspector General (OIG) — “three on audits in Bangladesh, Djibouti and Ghana, and two on investigations in Djibouti and South Africa” (11/5).
IRIN examines the controversy surrounding the Affordable Medicines Facility-malaria (AMFm), writing, “The argument over the way it operates has reignited ahead of a board meeting of the [Global Fund to Fight AIDS, Tuberculosis and Malaria] on 14-15 November, which is due to assess the success of the project and its reliance on private sector providers.” The news service reports on an evaluation of AMFm published recently in the Lancet and another paper by Oxfam criticizing the facility. The Global Fund Board, which administers AMFm, “is meeting in nine days to decide whether AMF has worked as was intended, and whether it should be continued, scaled up, or abandoned altogether,” IRIN writes (11/5).